Literature DB >> 19317379

Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia.

Gary Zammit1, Sherry Wang-Weigand, Murray Rosenthal, Xuejun Peng.   

Abstract

STUDY
OBJECTIVES: To evaluate the effect of ramelteon on middle-of-the-night balance, mobility, and memory in older insomniacs.
METHODS: Thirty-three older adults (age > or = 65 years) with insomnia were enrolled in a single-dose, 3-way crossover study of balance after bedtime administration of ramelteon, 8 mg; zolpidem, 10 mg (positive control); or placebo. Subjects were administered study medication 30 minutes before bedtime and were awakened 2 hours after dosing to evaluate balance (Sensory Organization Test), turning speed and stability, memory (immediate and delayed word recall), and adverse events. There was a 4- to 10-day washout between treatments.
RESULTS: Ramelteon or zolpidem (positive control) was compared with placebo. There were no differences between placebo and ramelteon on the Sensory Organization Test (p = 0.837), turn time (p = 0.776), or turn sway (p = 0.982). The positive control (zolpidem) did reveal significant impairments on the Sensory Organization Test, turn time, and turn sway (p < 0.001, all). Immediate and delayed memory recall were not significantly different with ramelteon (p = 0.683 and p = 0.650, respectively). Immediate recall declined significantly with zolpidem (p = 0.002). Adverse events were infrequent (ramelteon, n = 7; placebo, n = 7; zolpidem, n = 13); none were serious.
CONCLUSION: In older adults, ramelteon did not impair middle-of-the night balance, mobility, or memory relative to placebo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19317379      PMCID: PMC2637164     

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  33 in total

1.  Comparison of elderly nonfallers and fallers on performance measures of functional reach, sensory organization, and limits of stability.

Authors:  H W Wallmann
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2001-09       Impact factor: 6.053

2.  Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability.

Authors:  S M Evans; F R Funderburk; R R Griffiths
Journal:  J Pharmacol Exp Ther       Date:  1990-12       Impact factor: 4.030

3.  Recovery from hip fracture in eight areas of function.

Authors:  J Magaziner; W Hawkes; J R Hebel; S I Zimmerman; K M Fox; M Dolan; G Felsenthal; J Kenzora
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2000-09       Impact factor: 6.053

4.  Prevalence of sleep problems and quality of life in an older population.

Authors:  Carla R Schubert; Karen J Cruickshanks; Dayna S Dalton; Barbara E K Klein; Ronald Klein; David M Nondahl
Journal:  Sleep       Date:  2002-12       Impact factor: 5.849

5.  Zolpidem use and hip fractures in older people.

Authors:  P S Wang; R L Bohn; R J Glynn; H Mogun; J Avorn
Journal:  J Am Geriatr Soc       Date:  2001-12       Impact factor: 5.562

6.  1999 National Hospital Discharge Survey: annual summary with detailed diagnosis and procedure data.

Authors:  J R Popovic
Journal:  Vital Health Stat 13       Date:  2001-09

7.  The effect of falls and fall injuries on functioning in community-dwelling older persons.

Authors:  M E Tinetti; C S Williams
Journal:  J Gerontol A Biol Sci Med Sci       Date:  1998-03       Impact factor: 6.053

8.  Benzodiazepine use and hip fractures in the elderly: who is at greatest risk?

Authors:  Anita K Wagner; Fang Zhang; Stephen B Soumerai; Alexander M Walker; Jerry H Gurwitz; Robert J Glynn; Dennis Ross-Degnan
Journal:  Arch Intern Med       Date:  2004-07-26

9.  Sleep disturbances and chronic disease in older adults: results of the 2003 National Sleep Foundation Sleep in America Survey.

Authors:  Daniel Foley; Sonia Ancoli-Israel; Patricia Britz; James Walsh
Journal:  J Psychosom Res       Date:  2004-05       Impact factor: 3.006

Review 10.  Molecular pharmacology, regulation and function of mammalian melatonin receptors.

Authors:  Margarita L Dubocovich; Moises A Rivera-Bermudez; Matthew J Gerdin; Monica I Masana
Journal:  Front Biosci       Date:  2003-09-01
View more
  15 in total

Review 1.  Insomnia in the Elderly: A Review.

Authors:  Dhaval Patel; Joel Steinberg; Pragnesh Patel
Journal:  J Clin Sleep Med       Date:  2018-06-15       Impact factor: 4.062

2.  Ramelteon for Insomnia Related to Attention-Deficit/Hyperactivity Disorder (ADHD).

Authors:  Rachel E Fargason; Karen Gamble; Kristin T Avis; Rachel C Besing; Cherry W Jackson; Marshall E Cates; Roberta May
Journal:  Psychopharmacol Bull       Date:  2011-05-15

3.  Ramelteon prior to a short evening nap impairs neurobehavioral performance for up to 12 hours after awakening.

Authors:  Daniel A Cohen; Wei Wang; Elizabeth B Klerman; Shantha M W Rajaratnam
Journal:  J Clin Sleep Med       Date:  2010-12-15       Impact factor: 4.062

4.  Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening.

Authors:  Patricia Murphy; Dinesh Kumar; Gary Zammit; Russell Rosenberg; Margaret Moline
Journal:  J Clin Sleep Med       Date:  2020-02-06       Impact factor: 4.062

5.  Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects.

Authors:  Monique A J Mets; Juna M de Vries; Lieke M de Senerpont Domis; Edmund R Volkerts; Berend Olivier; Joris C Verster
Journal:  Sleep       Date:  2011-10-01       Impact factor: 5.849

Review 6.  Insomnia in Elderly Patients: Recommendations for Pharmacological Management.

Authors:  Vivien C Abad; Christian Guilleminault
Journal:  Drugs Aging       Date:  2018-09       Impact factor: 3.923

7.  Middle-of-the-night hypnotic use in a large national health plan.

Authors:  Thomas Roth; Patricia Berglund; Victoria Shahly; Alicia C Shillington; Judith J Stephenson; Ronald C Kessler
Journal:  J Clin Sleep Med       Date:  2013-07-15       Impact factor: 4.062

8.  The effects of acute treatment with ramelteon, triazolam, and placebo on driving performance, cognitive function, and equilibrium function in healthy volunteers.

Authors:  Akemi Miyata; Kunihiro Iwamoto; Naoko Kawano; Kunihiro Kohmura; Maeri Yamamoto; Branko Aleksic; Kazutoshi Ebe; Akiko Noda; Yukihiro Noda; Shuji Iritani; Norio Ozaki
Journal:  Psychopharmacology (Berl)       Date:  2014-12-24       Impact factor: 4.530

9.  Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.

Authors:  Patricia Murphy; Margaret Moline; David Mayleben; Russell Rosenberg; Gary Zammit; Kate Pinner; Shobha Dhadda; Quan Hong; Luigi Giorgi; Andrew Satlin
Journal:  J Clin Sleep Med       Date:  2017-11-15       Impact factor: 4.062

Review 10.  Sleep in older adults: normative changes, sleep disorders, and treatment options.

Authors:  Nalaka S Gooneratne; Michael V Vitiello
Journal:  Clin Geriatr Med       Date:  2014-06-12       Impact factor: 3.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.